CBS-0550 is a drug developed by Taisho Pharmaceutical, which acts as a potent and selective cannabinoid CB2 receptor agonist, with 1400x selectivity for CB2 over the related CB1 receptor. Unlike most cannabinoid agonists, CBS-0550 has good solubility in water, and in animal studies it was found to produce analgesic and anti-hyperalgesic effects.[1] A number of related compounds have been developed with similar properties.[2]

CBS-0550
Identifiers
  • N-[5-tert-butyl-2-(cyclopropylmethyl)-1-methylpyrazol-3-ylidene]-2-fluoro-3-(trifluoromethyl)benzamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC20H23F4N3O
Molar mass397.418 g·mol−1
3D model (JSmol)
  • C3CC3Cn1c(cc(C(C)(C)C)n1C)=N\C(=O)c2cccc(C(F)(F)F)c2F
  • InChI=1S/C20H23F4N3O/c1-19(2,3)15-10-16(27(26(15)4)11-12-8-9-12)25-18(28)13-6-5-7-14(17(13)21)20(22,23)24/h5-7,10,12H,8-9,11H2,1-4H3/b25-16+
  • Key:PABOWKPYVAFTRN-PCLIKHOPSA-N

See also

edit

References

edit
  1. ^ Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Yamaguchi T, et al. (February 2008). "Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action". Bioorganic & Medicinal Chemistry. 16 (3): 1111–24. doi:10.1016/j.bmc.2007.10.087. PMID 18006322.
  2. ^ Ohta H, Ishizaka T, Tatsuzuki M, Yoshinaga M, Iida I, Tomishima Y, et al. (November 2007). "N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability". Bioorganic & Medicinal Chemistry Letters. 17 (22): 6299–304. doi:10.1016/j.bmcl.2007.09.004. PMID 17884496.